全文获取类型
收费全文 | 73852篇 |
免费 | 5366篇 |
国内免费 | 445篇 |
专业分类
耳鼻咽喉 | 832篇 |
儿科学 | 2391篇 |
妇产科学 | 1879篇 |
基础医学 | 9248篇 |
口腔科学 | 1039篇 |
临床医学 | 10115篇 |
内科学 | 14191篇 |
皮肤病学 | 1228篇 |
神经病学 | 6102篇 |
特种医学 | 1958篇 |
外国民族医学 | 1篇 |
外科学 | 8416篇 |
综合类 | 1530篇 |
一般理论 | 81篇 |
预防医学 | 7407篇 |
眼科学 | 1983篇 |
药学 | 5049篇 |
中国医学 | 351篇 |
肿瘤学 | 5862篇 |
出版年
2023年 | 529篇 |
2022年 | 923篇 |
2021年 | 1789篇 |
2020年 | 1210篇 |
2019年 | 1708篇 |
2018年 | 2078篇 |
2017年 | 1563篇 |
2016年 | 1706篇 |
2015年 | 1973篇 |
2014年 | 2683篇 |
2013年 | 3713篇 |
2012年 | 5342篇 |
2011年 | 5636篇 |
2010年 | 3100篇 |
2009年 | 2771篇 |
2008年 | 4669篇 |
2007年 | 4765篇 |
2006年 | 4699篇 |
2005年 | 4592篇 |
2004年 | 4149篇 |
2003年 | 3760篇 |
2002年 | 3508篇 |
2001年 | 1350篇 |
2000年 | 1249篇 |
1999年 | 1168篇 |
1998年 | 788篇 |
1997年 | 598篇 |
1996年 | 499篇 |
1995年 | 402篇 |
1994年 | 403篇 |
1993年 | 395篇 |
1992年 | 580篇 |
1991年 | 554篇 |
1990年 | 511篇 |
1989年 | 493篇 |
1988年 | 436篇 |
1987年 | 445篇 |
1986年 | 403篇 |
1985年 | 354篇 |
1984年 | 302篇 |
1983年 | 222篇 |
1982年 | 184篇 |
1981年 | 184篇 |
1980年 | 159篇 |
1979年 | 179篇 |
1978年 | 120篇 |
1977年 | 110篇 |
1976年 | 97篇 |
1975年 | 101篇 |
1972年 | 83篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
3.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract
Purpose
Financial hardship can be a major cause of distress among persons with cancer, resulting in chronic stress and impacting physical and emotional health. This paper provides an analysis of the lived experience of cancer patients’ financial hardship from diagnosis to post-treatment. 相似文献4.
5.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
6.
7.
8.
9.
10.
Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung? 下载免费PDF全文
Kim Hein Lindahl Flemming Brandt Sørensen Søren Peter Jonstrup Karen Ege Olsen Siegfried Loeschke 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(4):289-297
The identification of EGFR mutations in non‐small‐cell lung cancer is important for selecting patients, who may benefit from treatment with EGFR tyrosine kinase inhibitors. The analysis is usually performed on cytological aspirates and/or histological needle biopsies, representing a small fraction of the tumour volume. The aim of the present investigation was to evaluate the diagnostic performance of this molecular test. We retrospectively included 201 patients with primary adenocarcinoma of the lung. EGFR mutation status (exon 19 deletions and exon 21 L858R point mutation) was evaluated on both pre‐operative biopsies (131 histological and 70 cytological) and on the surgical specimens, using PCR. Samples with low tumour cell fraction were assigned to laser micro‐dissection (LMD). We found nine (4.5%) patients with EGFR mutation in the lung tumour resections, but failed to identify mutation in one of the corresponding pre‐operative, cytological specimens. Several (18.4%) analyses of the pre‐operative biopsies were inconclusive, especially in case of biopsies undergoing LMD and regarding exon 21 analysis. Discrepancy of mutation status in one patient may reflect intra‐tumoural heterogeneity or technical issues. Moreover, several inconclusive results in the diagnostic biopsies reveal that attention must be paid on the suitability of pre‐operative biopsies for EGFR mutation analysis. 相似文献